Nucleic Acid Testing Market Trend, Share, Growth, Size Analysis and Forecast 2030

Nucleic Acid Testing Industry Prospective:

The global nucleic acid testing market size was worth around USD 3497.65 million in 2022 and is predicted to grow to around USD 6254.89 million by 2030 with a compound annual growth rate (CAGR) of roughly 7.65% between 2023 and 2030.

Request Free Sample

Nucleic Acid Testing Market: Overview

Nucleic acid testing (NAT) is a medical and research technique used for detecting nucleic acid sequences for further analysis and detection of particular species or subspecies of an organism. It is used for determining the presence of bacteria or viruses in a given sample acting as pathogens in tissue, blood, urine, and others. These testing methods differ from other methods since NATs depend on genetic components of the organisms such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) rather than the presence of antibodies and antigens. Nucleic acid testing is preferred in certain situations because this method allows rapid detection of a certain disease since the development of antigens or antibodies may take some time resulting in delayed detection. In almost all nucleic acid testing procedures, an amplification method is used that helps in increasing the genetic material. This step is required because certain genetic components can be extremely scarce and difficult to detect. In such conditions, NATs are referred to as nucleic acid amplification tests (NAATs) and methods such as strand displacement assay (SDA), polymerase chain reaction (PCR), and transcription-mediated assay (TMA). The nucleic acid testing market is expected to grow at a steady pace during the forecast period.

Key Insights:

• As per the analysis shared by our research analyst, the global nucleic acid testing market is estimated to grow annually at a CAGR of around 7.65% over the forecast period (2023-2030)
• In terms of revenue, the global nucleic acid testing market size was valued at around USD 3497.65 million in 2022 and is projected to reach USD 6254.89 million, by 2030.
• The nucleic acid testing market is projected to grow at a significant rate due to the growing number of HIV cases
• Based on indication segmentation, infectious diseases was predicted to show maximum market share in the year 2022
• Based on product type segmentation, nucleic-acid test kits was the leading segment in 2022
• On the basis of region, North America was the leading revenue generator in 2022

Request Free Sample

Nucleic Acid Testing Market: Growth Drivers

Growing number of HIV cases to create higher market growth

The global nucleic acid testing market is expected to grow owing to the increasing number of HIV cases across the globe. NATs are used extensively for detecting the presence of RNA or DNA corresponding to the human immunodeficiency virus (HIV). These viruses are known to attach cells present in human bodies that are responsible for fighting infection. Contracting the HIV means that the patient is more vulnerable to other diseases and infections. HIV can spread through coming in contact with specific body fluids of an HIV-positive patient. The most common reason for the growing spread of HIV conditions is unprotected intercourse or sharing an injection between multiple people. In case HIV is left untreated, it can result in (acquired immunodeficiency syndrome (AIDS). It is one of the medical conditions in the world that does not have any cure. Although there have significant strides made in the medical care of patients living with AIDS, the condition can severely impact the quality of life. As per statistics published by the World Health Organization (WHO), around 39 million across the globe will be living with HIV by the end of 2022. Factors such as increased awareness rate about the importance of frequent testing especially among sexually active people and higher availability of NAT kits have resulted in extensive market growth in the last few years.

COVID-19 was a triggering point for momentous growth in NAT procedures across the globe

Since 2022, nucleic acid testing procedures have gained extreme momentum. These tests have been extremely helpful in the early detection of the COVID-19 virus across the globe driving global market growth. The most popular variant during COVID-19 was PCR-based nucleic acid testing because these procedures provided quick and accurate results. The momentum has continued since then. For instance, in May 2023, the National Institute of Virology (NIV), Pune, India launched the first domestically-produced multiplex single-tube real-time RT-PCR test. It is a highly accurate nucleic acid testing method.

Nucleic Acid Testing Market: Restraints

Several technical limitations to restrict market growth

The nucleic acid testing industry players face several technical limitations when dealing with nucleic acid testing. For instance, the testing method is not beneficial in obtaining quantitative results in the case of large-scale clinical samples. The tests are extremely difficult to use for susceptibility testing. In addition to this, advanced PCR NATs can be expensive due to the complex nature of the testing procedure. While the test results are highly accurate, conducting advanced nucleic acid tests demands the use of dedicated infrastructure equipped with all essential systems and technologies.

Nucleic Acid Testing Market: Opportunities

Increasing launch of new NAT processes and rising research in associated technology to deliver excellent expansion possibilities

The global nucleic acid testing market growth trend appears promising due to the increasing number of recent advancements in nucleic acid testing procedures, kits, and supporting systems. For instance, in March 2021, Promega Corporation launched XpressAmp™ Direct Amplification Reagents. This development will allow end-users to prepare samples without the need to extract RNA. It helped laboratories dealing with COVID-19 testing eliminate one of the most prominent bottlenecks in testing procedures. The laboratories could directly move to the PCR amplification process. Furthermore, the increasing use of NATs in emerging economies along with rising investments in the regional healthcare infrastructure. In September 2021, Thermo Fisher Scientific announced that it will start manufacturing nucleic acid testing kits in India as researchers view the tools with applications beyond COVID-19 testing. The test kits developed by Thermo Fisher can analyze up to 96 samples within 30 minutes. On the other hand, in April 2022, Beijing city in China witnessed the launch of massive nucleic acid testing for nearly 90% of its residents as  COVID-19 infections continued to be reported in the dense city.

Nucleic Acid Testing Market: Challenges

Lack of infrastructure and quality management to challenge market expansion

The global nucleic acid testing market growth is expected to be challenged due to the lack of infrastructure that aids manufacturing and application of NATs in addition to the issues faced in managing the quality of nucleic acid testing procedures. Furthermore, managing the vast scale of data generated during NAT procedures adds to growth restraints.

Nucleic Acid Testing Market: Segmentation

The global nucleic acid testing market is segmented based on indication, end-user verticals, product type, and region.

Based on indication, the global market segments are cancer, infectious diseases, personalized medicine, forensic testing, and others. In 2022, the highest demand was observed in the infectious diseases segment since nucleic acid testing is most significantly used for the rapid detection of contagious diseases that spread quickly from one person to another. The segmental growth in 2022 was a result of increased use of RT-PCR tests during COVID-19. As per research, the current best-in-class assays are known to showcase a limit of detection (LoD) of ~100 copies of viral RNA per milliliter of transport media.

Based on end-user verticals, the nucleic acid testing industry is segmented into academic & research organizations, pathology laboratories, hospitals & clinics, and others.

Based on product type, the global market fragments are consumables and nucleic-acid test kits. The latter segment is further divided into ligase chain reaction (LCR), polymerase chain reaction (PCR), transcription-mediated amplification (TMA), and whole genome sequencing. In 2022, the nucleic-acid test kit segment generated the highest growth rate propelled by high demand in the PCR sub-segment. This method can convert millions of specific DNA samples into billions of copies within a short period. In most cases, RT-PCR tests deliver results in 4 hours.

Nucleic Acid Testing Market: Report Scope

Nucleic Acid Testing Market: Regional Analysis

North America to witness the highest growth rate during the coming period

The global nucleic acid testing market is expected to be led by North America during the forecast period. The US will act as the major regional shareholder driven by the presence of an evolving and globally prominent medical and drug research infrastructure. The US is home to some of the largest pharmaceutical giants constantly working toward developing novel testing methods to detect infectious diseases and develop efficient treatments. Furthermore, the US is highly popular for running large-scale healthcare programs for the medical safety of its population. In 2018, the University of Glasgow-led project was awarded USD 1.85 million to conduct rapid testing in rural and remote locations. The funds were also used for the development of efficient tests for new parasitic diseases. Moreover, the region has a rich ecosystem that supports the development of personalized medicine. As per research, Pfizer is predicted to lead the way for customized medicines in the coming years. In July 2023, Pfizer announced that it would invest USD 100 million in association with venture firm Flagship Pioneering for the development of 10 novel potential drugs including infectious diseases.

Nucleic Acid Testing Market: Competitive Analysis

The global nucleic acid testing market is led by players like:

• Thermo Fisher Scientific
• Roche Diagnostics
• Hologic
• Luminex Corporation
• Qiagen
• DiaSorin
• Bio-Rad Laboratories
• BioMérieux
• Abbott Laboratories
• Grifols
• Cepheid
• Siemens Healthineers
• Exact Sciences Corporation

The global nucleic acid testing market is segmented as follows:

By Indication

• Cancer
• Infectious Diseases
• Personalized Medicine
• Forensic Testing
• Others

By End-User Verticals

• Academic & Research Organizations
• Pathology Laboratories
• Hospital & Clinics
• Others

By Product Type

• Consumables
• Nucleic-Acid Test Kits
  • Ligase Chain Reaction (LCR)
  • Polymerase Chain Reaction (PCR)
  • Transcription-Mediated Amplification (TMA)
  • Whole Genome Sequencing

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa